首页 > 最新文献

Infectious Diseases: News, Opinions, Training最新文献

英文 中文
Polymorphism of genes in patients with new coronavirus infection COVID-19 新型冠状病毒感染COVID-19患者基因多态性分析
Q4 Social Sciences Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-3-130-137
B. Kantemirova, V. Vasilkova
The incidence of new coronavirus infection (COVID-19) varies significantly between countries and continents. Until now, there has been no clear explanation for this observation. Epidemiological studies have demonstrated a large difference in infection and mortality rates between men and women. This may be due to the gender difference in the polymorphism of genes linked to the X chromosome, which play an important role in the immune response. In addition, there is a different degree of severity of the disease: from an asymptomatic course and mild symptoms to a life-threatening condition requiring hospitalization in the intensive care unit and artificial lung ventilation. Several factors are associated with the severity of COVID-19, such as elderly age, multiple comorbid diseases, smoking, hypercholesterolemia, etc. However, we observe that severe disease is also observed in patients who do not have the above risk factors. In recent months, severe forms of COVID-19 have been reported in children, including early infancy. In this connection, it is relevant, in our opinion, to focus the problem on genetic factors, such as the carriage of single-nucleotide polymorphisms, which can affect susceptibility to infection and variability in the severity of the disease. © 2022 Sorbtsionnye i Khromatograficheskie Protsessy. All rights reserved.
新型冠状病毒感染(COVID-19)的发病率在各国和各大洲之间差异很大。到目前为止,对这一观察结果还没有明确的解释。流行病学研究表明,男女之间的感染率和死亡率有很大差异。这可能是由于与X染色体相关的基因多态性的性别差异,而X染色体在免疫反应中起着重要作用。此外,该疾病的严重程度也不同:从无症状和轻微症状到危及生命的情况,需要在重症监护病房住院并进行人工肺通气。有几个因素与COVID-19的严重程度有关,如老年、多种合并症、吸烟、高胆固醇血症等。然而,我们观察到,在没有上述危险因素的患者中也观察到严重的疾病。近几个月来,包括婴幼儿在内的儿童中报告了严重形式的COVID-19。在这方面,我们认为,把问题的重点放在遗传因素上是相关的,例如携带单核苷酸多态性,它可以影响对感染的易感性和疾病严重程度的可变性。©2022 Sorbtsionnye i Khromatograficheskie protesessy。版权所有。
{"title":"Polymorphism of genes in patients with new coronavirus infection COVID-19","authors":"B. Kantemirova, V. Vasilkova","doi":"10.33029/2305-3496-2022-11-3-130-137","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-3-130-137","url":null,"abstract":"The incidence of new coronavirus infection (COVID-19) varies significantly between countries and continents. Until now, there has been no clear explanation for this observation. Epidemiological studies have demonstrated a large difference in infection and mortality rates between men and women. This may be due to the gender difference in the polymorphism of genes linked to the X chromosome, which play an important role in the immune response. In addition, there is a different degree of severity of the disease: from an asymptomatic course and mild symptoms to a life-threatening condition requiring hospitalization in the intensive care unit and artificial lung ventilation. Several factors are associated with the severity of COVID-19, such as elderly age, multiple comorbid diseases, smoking, hypercholesterolemia, etc. However, we observe that severe disease is also observed in patients who do not have the above risk factors. In recent months, severe forms of COVID-19 have been reported in children, including early infancy. In this connection, it is relevant, in our opinion, to focus the problem on genetic factors, such as the carriage of single-nucleotide polymorphisms, which can affect susceptibility to infection and variability in the severity of the disease. © 2022 Sorbtsionnye i Khromatograficheskie Protsessy. All rights reserved.","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Humoral and cellular immune responses in children 3–6 years old with infectious mononucleosis caused by primary and reactivation of Epstein–Barr viral infection 原发性和再激活eb病毒感染引起的3-6岁感染性单核细胞增多症患儿的体液和细胞免疫应答
Q4 Social Sciences Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-2-57-63
E. Kashuba, M. Antonova, T. Drozdova, O. Rychkova, O. Lyubimtseva, L. V. Khanipova, N. Ogoshkova, Y. Chekhova, A. Beltikova
{"title":"Humoral and cellular immune responses in children 3–6 years old with infectious mononucleosis caused by primary and reactivation of Epstein–Barr viral infection","authors":"E. Kashuba, M. Antonova, T. Drozdova, O. Rychkova, O. Lyubimtseva, L. V. Khanipova, N. Ogoshkova, Y. Chekhova, A. Beltikova","doi":"10.33029/2305-3496-2022-11-2-57-63","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-2-57-63","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A case of meningococcal pneumonia complicated by bilateral pleurisy, pericarditis 脑膜炎球菌性肺炎并发双侧胸膜炎、心包炎1例
Q4 Social Sciences Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-4-127-133
I. Davydova, T. Smirnova, O. Litvinova, I.Ch. Partilchaeva
{"title":"A case of meningococcal pneumonia complicated by bilateral pleurisy, pericarditis","authors":"I. Davydova, T. Smirnova, O. Litvinova, I.Ch. Partilchaeva","doi":"10.33029/2305-3496-2022-11-4-127-133","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-4-127-133","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevention of COVID-19 coronavirus infection with aminodihydrophthalazinedione sodium (Galavit®) in medical staff of the “red zone”: results of the multicenter observational study 氨基二氢酞嗪二酮钠(Galavit®)预防“红区”医护人员COVID-19冠状病毒感染的多中心观察研究结果
Q4 Social Sciences Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-1-93-101
S. Kolesov, M. Mozheyko, G. Trufanov, D. Gorbatyuk
COVID-hospital healthcare workers belong to a high-risk SARS-CoV-2 infection. The aminodihydrophthalazinedione sodium (Galavit®) belongs to the group of immunomodulatory and anti-inflammatory drugs. It has been shown that aminodihydrophthalazinedione sodium is effective in the prevention of acute respiratory infections, respiratory tract diseases and ENT-organs of bacterial and viral etiology. The purpose of the study. To evaluate the effectiveness and safety of immunoprophylaxis of new coronavirus infection (COVID-19) with aminodihydrophthalazinedione sodium in healthcare workers providing medical care in the “red zone”. Material and methods. A multicenter prospective-retrospective observational comparative non-randomized study in healthcare workers providing medical care in the “red zone” was conducted. 428 participants were included in the study: the observation group - healthcare workers who administered aminodihydrophthalazinedione sodium (Galavit®) for prophylactic purposes (n=214), and control group (n=214). The observation period of the participants or the period of collecting retrospective data in the study was 30 days. The results of PCR tests and tests for antibodies to the SARS-CoV-2 were analyzed, clinical status (COVID-19 in any form) was assessed. Descriptive statistic methods and Pearson χ2 test were used. The risk ratios, odds ratios and 95% confidence intervals were calculated with them. The influence of potential confounding factors (age, gender, work place in clinical site, the presence or absence of concomitant disease) on the clinical status were analyzed using logistic regression. The analysis of propensity score matching was carried out. The Stata/IC 14.2 for Windows software used for statistical analysis. Results and discussion. Observational study results describe the risk ratios and odds ratios of infection with a new coronavirus (COVID-19) in healthcare workers providing medical care in the “red zone” considering prophylactic administration of aminodihydrophthalazinedione sodium (Galavit®). 205 (95.8%) participants in the group of healthcare workers who took aminodihydrophthalazinedione sodium (Galavit®) for prophylactic purposes and 194 (90.7%) participants in control group had a negative PCR test during the observation period, χ2=4.48, p=0.034. The risk of a positive status according to the PCR test for 30 days in the preventive group was 0,04, and in the control group 0.09. The risk difference was -0.05 [95% confidence interval (CI) -0.099;-0.004]. The adjusted odds ratio using multiple logistic regression was - 0.41 (95% CI 0.18-0.93). No adverse events were observed during the prophylactic administration of aminodihydrophthalazinedione sodium over 30 days. Conclusion. Galavit® preventive administration in a tablet form at a dose of 50-100 mg per day by employees of medical institutions providing medical care to patients with CIVID-19 significantly reduces the risk of SARS-CoV-2 infection and more than 2 times incr
新冠医院医护人员属于SARS-CoV-2高危感染人群。氨基二氢酞嗪二酮钠(Galavit®)属于免疫调节和抗炎药物。研究表明,氨基二氢酞嗪二酮钠对急性呼吸道感染、呼吸道疾病和由细菌和病毒引起的鼻窦器官疾病有有效的预防作用。研究的目的。目的评价氨基二氢酞嗪二酮钠在“红区”医护人员免疫预防新型冠状病毒感染(COVID-19)的有效性和安全性。材料和方法。对在“红区”提供医疗服务的医护人员进行了一项多中心前瞻性-回顾性观察性比较非随机研究。428名参与者被纳入研究:观察组-以预防为目的使用氨基二氢酞嗪二酮钠(Galavit®)的医护人员(n=214)和对照组(n=214)。研究中参与者的观察期或回顾性资料收集期为30天。分析PCR检测和SARS-CoV-2抗体检测结果,评估临床状态(任何形式的COVID-19)。采用描述性统计方法和Pearson χ2检验。用它们计算风险比、优势比和95%置信区间。采用logistic回归分析潜在混杂因素(年龄、性别、临床工作场所、有无伴发疾病)对临床状态的影响。进行倾向得分匹配分析。采用Stata/IC 14.2 for Windows软件进行统计分析。结果和讨论。观察性研究结果描述了在“红区”提供医疗服务的医护人员在考虑预防性使用氨基二氢酞嗪二酮钠(Galavit®)的情况下感染新型冠状病毒(COVID-19)的风险比和优势比。观察期间,预防使用氨基二氢酞嗪二酮钠(Galavit®)的医护人员组有205人(95.8%)、对照组有194人(90.7%)PCR检测阴性,χ2=4.48, p=0.034。预防组30 d PCR阳性危险度为0.04,对照组为0.09。风险差异为-0.05[95%可信区间(CI) -0.099;-0.004]。多重logistic回归校正优势比为- 0.41 (95% CI 0.18-0.93)。预防性使用氨基二氢酞嗪二酮钠30天未见不良事件发生。结论。为covid -19患者提供医疗服务的医疗机构员工每天服用50-100毫克的Galavit®预防片剂,可显著降低感染SARS-CoV-2的风险,并使未感染新冠状病毒的几率增加2倍以上。Galavit®以50- 100mg的剂量给药30天耐受性良好,无不良事件记录。©2022作者所有。
{"title":"Prevention of COVID-19 coronavirus infection with aminodihydrophthalazinedione sodium (Galavit®) in medical staff of the “red zone”: results of the multicenter observational study","authors":"S. Kolesov, M. Mozheyko, G. Trufanov, D. Gorbatyuk","doi":"10.33029/2305-3496-2022-11-1-93-101","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-1-93-101","url":null,"abstract":"COVID-hospital healthcare workers belong to a high-risk SARS-CoV-2 infection. The aminodihydrophthalazinedione sodium (Galavit®) belongs to the group of immunomodulatory and anti-inflammatory drugs. It has been shown that aminodihydrophthalazinedione sodium is effective in the prevention of acute respiratory infections, respiratory tract diseases and ENT-organs of bacterial and viral etiology. The purpose of the study. To evaluate the effectiveness and safety of immunoprophylaxis of new coronavirus infection (COVID-19) with aminodihydrophthalazinedione sodium in healthcare workers providing medical care in the “red zone”. Material and methods. A multicenter prospective-retrospective observational comparative non-randomized study in healthcare workers providing medical care in the “red zone” was conducted. 428 participants were included in the study: the observation group - healthcare workers who administered aminodihydrophthalazinedione sodium (Galavit®) for prophylactic purposes (n=214), and control group (n=214). The observation period of the participants or the period of collecting retrospective data in the study was 30 days. The results of PCR tests and tests for antibodies to the SARS-CoV-2 were analyzed, clinical status (COVID-19 in any form) was assessed. Descriptive statistic methods and Pearson χ2 test were used. The risk ratios, odds ratios and 95% confidence intervals were calculated with them. The influence of potential confounding factors (age, gender, work place in clinical site, the presence or absence of concomitant disease) on the clinical status were analyzed using logistic regression. The analysis of propensity score matching was carried out. The Stata/IC 14.2 for Windows software used for statistical analysis. Results and discussion. Observational study results describe the risk ratios and odds ratios of infection with a new coronavirus (COVID-19) in healthcare workers providing medical care in the “red zone” considering prophylactic administration of aminodihydrophthalazinedione sodium (Galavit®). 205 (95.8%) participants in the group of healthcare workers who took aminodihydrophthalazinedione sodium (Galavit®) for prophylactic purposes and 194 (90.7%) participants in control group had a negative PCR test during the observation period, χ2=4.48, p=0.034. The risk of a positive status according to the PCR test for 30 days in the preventive group was 0,04, and in the control group 0.09. The risk difference was -0.05 [95% confidence interval (CI) -0.099;-0.004]. The adjusted odds ratio using multiple logistic regression was - 0.41 (95% CI 0.18-0.93). No adverse events were observed during the prophylactic administration of aminodihydrophthalazinedione sodium over 30 days. Conclusion. Galavit® preventive administration in a tablet form at a dose of 50-100 mg per day by employees of medical institutions providing medical care to patients with CIVID-19 significantly reduces the risk of SARS-CoV-2 infection and more than 2 times incr","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19: the efficacy and safety of anticoagulant, glucocorticosteroid therapy and metabolic COVID-19:抗凝血剂、糖皮质激素治疗和代谢的有效性和安全性
Q4 Social Sciences Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-1-47-56
D. Salivonchyk, I. Stoma, E. Dotsenko, N.N. Kudenchuk, E. Salivonchyk, I. A. Khudyakov, M. N. Menshakova, E.I. Malashchenko, S. Salivonchyk, K.O. Bondareva, E. Stepanets, O. Konovalova, E.V. Kuhoreva
Objective: assessment of the efficacy and safety of the use of anticoagulant, glucocorticosteroid, metabolic therapy in patients with COVID-19 at the inpatient stage of treatment. Material and methods. In February 2021, a prospective, randomized, single-center, continuous comparative study was organized on the basis of the Gomel City Clinical Hospital No. 3, which included 827 patients with moderate and severe clinical course of COVID-19. Results. Stratification of the risks of an unfavorable outcome in patients with moderate and severe clinical course of COVID-19 made it possible to optimize treatment, with the selection of optimal doses of anticoagulant and glucocorticosteroid therapy, which led to an increase in patient survival. A high level of blood lactate reflects the degree of damage to the lung tissue, the severity of the course of the disease and requires an increase in the dose of anticoagulant therapy. The use of thiotriazoline effectively reduces the level of lactate, which makes it possible to restore the energy balance of the cell. Conclusion. The use of therapeutic (intermediate) doses of anticoagulant and optimal glucorticosteroid therapy in patients at high risk of poor outcomes with moderate and severe clinical course of COVID-19, can increase the survival rate from 82.1 to 96.8%, p<0.0001. The appointment of anticoagulant therapy was complicated by “minor” bleeding in 2.13% in the main group, in 2.11% in the control group, p>0.05, and the use of glucocorticosteroids was complicated by newly diagnosed diabetes mellitus (2.13% in the main group, 1.81% in the control group, p>0.05), which allows us to consider the therapy used is safe. The use of the metabolic, antioxidant agent thiotriazoline in patients with an LDH level of more than 800 U/L and with a high risk of an unfavorable outcome led to a decrease in LDH within five days of treatment by 447.9 U/L in the main group compared with the control group by 124.0 U/L (p=0.0001), which was accompanied by an improvement in the general condition, increased physical activity, and an earlier start of rehabilitation. © 2022 by the authors.
目的:评价新型冠状病毒肺炎患者住院期使用抗凝血剂、糖皮质激素、代谢治疗的疗效和安全性。材料和方法。2021年2月,在戈梅利市第三临床医院的基础上,组织了一项前瞻性、随机、单中心、连续的比较研究,纳入了827例中重度临床病程的COVID-19患者。结果。对COVID-19中重度临床病程患者的不良结局风险进行分层,可以优化治疗,选择最佳剂量的抗凝血剂和糖皮质激素治疗,从而提高患者的生存率。血乳酸水平高反映了肺组织的损伤程度、病程的严重程度,需要增加抗凝治疗的剂量。硫代三唑啉的使用有效地降低了乳酸水平,这使得恢复细胞的能量平衡成为可能。结论。中重度临床病程的不良预后高危患者使用治疗(中)剂量的抗凝剂和最佳糖皮质激素治疗可将生存率从82.1%提高到96.8%,p < 0.05,且糖皮质激素的使用合并新诊断的糖尿病(主组2.13%,对照组1.81%,p < 0.05),我们认为所使用的治疗是安全的。在LDH水平超过800 U/L且预后不良风险高的患者中使用代用抗氧化剂硫代三唑啉,治疗后5天内,主组LDH较对照组降低447.9 U/L,降低124.0 U/L (p=0.0001),并伴有一般情况的改善、体力活动的增加和康复的早期开始。©2022作者所有。
{"title":"COVID-19: the efficacy and safety of anticoagulant, glucocorticosteroid therapy and metabolic","authors":"D. Salivonchyk, I. Stoma, E. Dotsenko, N.N. Kudenchuk, E. Salivonchyk, I. A. Khudyakov, M. N. Menshakova, E.I. Malashchenko, S. Salivonchyk, K.O. Bondareva, E. Stepanets, O. Konovalova, E.V. Kuhoreva","doi":"10.33029/2305-3496-2022-11-1-47-56","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-1-47-56","url":null,"abstract":"Objective: assessment of the efficacy and safety of the use of anticoagulant, glucocorticosteroid, metabolic therapy in patients with COVID-19 at the inpatient stage of treatment. Material and methods. In February 2021, a prospective, randomized, single-center, continuous comparative study was organized on the basis of the Gomel City Clinical Hospital No. 3, which included 827 patients with moderate and severe clinical course of COVID-19. Results. Stratification of the risks of an unfavorable outcome in patients with moderate and severe clinical course of COVID-19 made it possible to optimize treatment, with the selection of optimal doses of anticoagulant and glucocorticosteroid therapy, which led to an increase in patient survival. A high level of blood lactate reflects the degree of damage to the lung tissue, the severity of the course of the disease and requires an increase in the dose of anticoagulant therapy. The use of thiotriazoline effectively reduces the level of lactate, which makes it possible to restore the energy balance of the cell. Conclusion. The use of therapeutic (intermediate) doses of anticoagulant and optimal glucorticosteroid therapy in patients at high risk of poor outcomes with moderate and severe clinical course of COVID-19, can increase the survival rate from 82.1 to 96.8%, p<0.0001. The appointment of anticoagulant therapy was complicated by “minor” bleeding in 2.13% in the main group, in 2.11% in the control group, p>0.05, and the use of glucocorticosteroids was complicated by newly diagnosed diabetes mellitus (2.13% in the main group, 1.81% in the control group, p>0.05), which allows us to consider the therapy used is safe. The use of the metabolic, antioxidant agent thiotriazoline in patients with an LDH level of more than 800 U/L and with a high risk of an unfavorable outcome led to a decrease in LDH within five days of treatment by 447.9 U/L in the main group compared with the control group by 124.0 U/L (p=0.0001), which was accompanied by an improvement in the general condition, increased physical activity, and an earlier start of rehabilitation. © 2022 by the authors.","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69483939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Methodology of formation of an individual professional development trajectory of health care managers 形成卫生保健管理人员个人专业发展轨迹的方法学
Q4 Social Sciences Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-2-106-111
N. Naygovzina, E. V. Zimina, Yu.S. Titkova, N. Makarova, E.P. Vasilyeva, Z.L. Goncharevskaya, M. Patrushev, E.A. Tsvetkova, M. Navarkin, E. Korchuganova, V. Deriushkin
{"title":"Methodology of formation of an individual professional development trajectory of health care managers","authors":"N. Naygovzina, E. V. Zimina, Yu.S. Titkova, N. Makarova, E.P. Vasilyeva, Z.L. Goncharevskaya, M. Patrushev, E.A. Tsvetkova, M. Navarkin, E. Korchuganova, V. Deriushkin","doi":"10.33029/2305-3496-2022-11-2-106-111","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-2-106-111","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
National calendar of preventive vaccinations: present and future 国家预防性疫苗接种日程表:现在和未来
Q4 Social Sciences Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-2-112-119
M. Kostinov, G. G. Kharseeva, A. V. Chepusova
In the context of a pandemic of a new coronavirus infection, vaccine prophylaxis within the framework of the National Calendar of Preventive Vaccinations (NCPV) is an absolute priority in the fight against infectious diseases. The lecture presents the structure and features of the NCPV, the main directions of its improvement, information on the priority infections for vaccination. The strategy of immunization throughout life, which guarantees the creation of maximum protection against infections and preservation of the optimal level of health of people without age restrictions, is considered. Information is provided on approaches to vaccination of various patient populations against new coronavirus, pertussis, pneumococcal, and rotavirus infections. The presented lecture materials can be useful both to medical students and doctors of various specialties (infectious disease specialists, pediatricians, epidemiologists, bacteriologists). © 2022 by the authors.
在新型冠状病毒感染大流行的背景下,在《国家预防性疫苗接种日历》框架内进行疫苗预防是防治传染病的绝对优先事项。讲座介绍了NCPV的结构和特点,改进的主要方向,疫苗接种的重点感染信息。审议了终身免疫战略,该战略保证最大限度地防止感染,并在没有年龄限制的情况下保持人们的最佳健康水平。提供了各种患者群体预防新型冠状病毒、百日咳、肺炎球菌和轮状病毒感染的疫苗接种方法的信息。所提供的讲座材料对医学生和不同专业的医生(传染病专家、儿科医生、流行病学家、细菌学家)都很有用。©2022作者所有。
{"title":"National calendar of preventive vaccinations: present and future","authors":"M. Kostinov, G. G. Kharseeva, A. V. Chepusova","doi":"10.33029/2305-3496-2022-11-2-112-119","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-2-112-119","url":null,"abstract":"In the context of a pandemic of a new coronavirus infection, vaccine prophylaxis within the framework of the National Calendar of Preventive Vaccinations (NCPV) is an absolute priority in the fight against infectious diseases. The lecture presents the structure and features of the NCPV, the main directions of its improvement, information on the priority infections for vaccination. The strategy of immunization throughout life, which guarantees the creation of maximum protection against infections and preservation of the optimal level of health of people without age restrictions, is considered. Information is provided on approaches to vaccination of various patient populations against new coronavirus, pertussis, pneumococcal, and rotavirus infections. The presented lecture materials can be useful both to medical students and doctors of various specialties (infectious disease specialists, pediatricians, epidemiologists, bacteriologists). © 2022 by the authors.","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulating vaccination: a comparative study 规范疫苗接种:一项比较研究
Q4 Social Sciences Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-2-14-18
K. Goyal, K. Dosajh
Обязательная вакцинация – важный элемент охраны общественного здоровья. Она позволила всем странам эффективно бороться с рядом заболеваний, таких как оспа и полиомиелит. Государства, как правило, проводят политику обязательной вакцинации, чтобы предотвратить распространение болезней на основании принципа коллективного иммунитета. Однако всякий раз при возникновении какого-либо нежелательного эффекта такая практика обязательной вакцинации поднимает вопросы, касающиеся рисков, связанных с введением вакцин. В США проблема обязательной вакцинации и ее правовых основ актуальна с начала XX в., за это время сформировалась устоявшаяся система решения этих вопросов. Изучение системы обязательной вакцинации в США чрезвычайно важно, поскольку Индия, активно участвующая в программе вакцинации, не имеет эффективного механизма правовой защиты в области вакцинопрофилактики, прообразом которой может стать система, существующая в США.
强制接种疫苗是公共卫生的重要组成部分。它使所有国家能够有效地对抗诸如天花和小儿麻痹症等几种疾病。各国通常采取强制性疫苗政策,以防止疾病在集体免疫的基础上传播。然而,每当出现不良影响时,强制接种疫苗的做法就会引发有关疫苗风险的问题。在美国,强制性疫苗的问题及其法律基础自20世纪初以来一直是一个紧迫的问题。研究美国的强制性疫苗系统至关重要,因为积极参与疫苗计划的印度在疫苗预防方面没有有效的补救机制,而美国的疫苗预防系统可能就是这样。
{"title":"Regulating vaccination: a comparative study","authors":"K. Goyal, K. Dosajh","doi":"10.33029/2305-3496-2022-11-2-14-18","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-2-14-18","url":null,"abstract":"Обязательная вакцинация – важный элемент охраны общественного здоровья. Она позволила всем странам эффективно бороться с рядом заболеваний, таких как оспа и полиомиелит. Государства, как правило, проводят политику обязательной вакцинации, чтобы предотвратить распространение болезней на основании принципа коллективного иммунитета. Однако всякий раз при возникновении какого-либо нежелательного эффекта такая практика обязательной вакцинации поднимает вопросы, касающиеся рисков, связанных с введением вакцин. В США проблема обязательной вакцинации и ее правовых основ актуальна с начала XX в., за это время сформировалась устоявшаяся система решения этих вопросов. Изучение системы обязательной вакцинации в США чрезвычайно важно, поскольку Индия, активно участвующая в программе вакцинации, не имеет эффективного механизма правовой защиты в области вакцинопрофилактики, прообразом которой может стать система, существующая в США.","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and laboratory characteristics of new coronaviral infection (COVID-19) in children 儿童新型冠状病毒感染(COVID-19)的临床和实验室特征
Q4 Social Sciences Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-2-32-37
R. Murzabaeva, D.A. Valishin, N.A. Abrashina, L.V. Murzagaleeva, A.D. Valishina
Another rise in the incidence of a new coronavirus infection (COVID-19), due to the penetration of the SARS-CoV-2 delta strain into Russia in the second half of April 2021, is characterized by rapid spread, severe course in adults and an increase in cases of the disease among children. The aim of the work is to assess the clinical and laboratory parameters of a new coronavirus infection (COVID-19) in children. Material and methods. The results of clinical and laboratory examination and complex therapy of 95 children with moderate and severe forms of COVID-19, hospitalized in the Republican Clinical Infectious Diseases Hospital in Ufa from May to September 2021, are presented. Results. The anamnesis of the disease and life, epidemiological, clinical and laboratory, instrumental data obtained during the examination of children with COVID-19 in the course of the disease were studied. Among the clinical manifestations in children, symptoms of acute respiratory infection (37.9±4.98%), pneumonia without respiratory failure (26.3±4.52%), pneumonia with acute respiratory failure (33.7±4.85%). In 2 patients of the first months of life (2.1±1.47%), against the background of a aggravated premorbid background, immunodeficiency, COVID-19 proceeded in an extremely severe form with a fatal outcome. Conclusion. The clinical manifestations of COVID-19 are similar in children and adults, but differ in the frequency of respiratory symptoms. A severe course with a fatal outcome was registered in children in the first months of life with a burdened premorbid background. © Infectious Diseases: News, Opinions, Training 2022.
由于SARS-CoV-2三角洲病毒株于2021年4月下半月渗透到俄罗斯,新型冠状病毒感染(COVID-19)的发病率再次上升,其特点是传播迅速,成人病程严重,儿童病例增加。这项工作的目的是评估儿童新型冠状病毒感染(COVID-19)的临床和实验室参数。材料和方法。报告2021年5月至9月在乌法共和国临床传染病医院住院的95例中、重度新冠肺炎患儿的临床、实验室检查和综合治疗结果。结果。对儿童COVID-19发病过程中疾病和生活的记忆、流行病学、临床和实验室、仪器检查资料进行了研究。患儿临床表现中以急性呼吸道感染为主(37.9±4.98%),肺炎伴呼吸衰竭为主(26.3±4.52%),肺炎伴急性呼吸衰竭为主(33.7±4.85%)。2例出生后1个月的患者(2.1±1.47%),在病前背景、免疫缺陷加重的背景下,COVID-19以极其严重的形式发展,并导致死亡。结论。COVID-19在儿童和成人中的临床表现相似,但在呼吸道症状的频率上有所不同。在出生头几个月具有负担的病前背景的儿童中记录了一个具有致命结果的严重过程。©传染病:新闻、观点、培训2022。
{"title":"Clinical and laboratory characteristics of new coronaviral infection (COVID-19) in children","authors":"R. Murzabaeva, D.A. Valishin, N.A. Abrashina, L.V. Murzagaleeva, A.D. Valishina","doi":"10.33029/2305-3496-2022-11-2-32-37","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-2-32-37","url":null,"abstract":"Another rise in the incidence of a new coronavirus infection (COVID-19), due to the penetration of the SARS-CoV-2 delta strain into Russia in the second half of April 2021, is characterized by rapid spread, severe course in adults and an increase in cases of the disease among children. The aim of the work is to assess the clinical and laboratory parameters of a new coronavirus infection (COVID-19) in children. Material and methods. The results of clinical and laboratory examination and complex therapy of 95 children with moderate and severe forms of COVID-19, hospitalized in the Republican Clinical Infectious Diseases Hospital in Ufa from May to September 2021, are presented. Results. The anamnesis of the disease and life, epidemiological, clinical and laboratory, instrumental data obtained during the examination of children with COVID-19 in the course of the disease were studied. Among the clinical manifestations in children, symptoms of acute respiratory infection (37.9±4.98%), pneumonia without respiratory failure (26.3±4.52%), pneumonia with acute respiratory failure (33.7±4.85%). In 2 patients of the first months of life (2.1±1.47%), against the background of a aggravated premorbid background, immunodeficiency, COVID-19 proceeded in an extremely severe form with a fatal outcome. Conclusion. The clinical manifestations of COVID-19 are similar in children and adults, but differ in the frequency of respiratory symptoms. A severe course with a fatal outcome was registered in children in the first months of life with a burdened premorbid background. © Infectious Diseases: News, Opinions, Training 2022.","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IL28B genetic polymorphism in chronic viral hepatitis 慢性病毒性肝炎中IL28B基因多态性的研究
Q4 Social Sciences Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-2-64-68
M. Abdukadirova, A. Khikmatullaeva, N. Ibadullaeva, E. Musabaev, V.Sh. Rakhimova, N. Yarmukhamedova, I. Egamova, L. Lokteva
{"title":"IL28B genetic polymorphism in chronic viral hepatitis","authors":"M. Abdukadirova, A. Khikmatullaeva, N. Ibadullaeva, E. Musabaev, V.Sh. Rakhimova, N. Yarmukhamedova, I. Egamova, L. Lokteva","doi":"10.33029/2305-3496-2022-11-2-64-68","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-2-64-68","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Infectious Diseases: News, Opinions, Training
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1